Hepatocellular carcinoma drug resistance models
Abstract Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. Although drug therapy has been well developed and applied, its clinical efficacy is limited due to primary or acquired drug resistance in most HCC patients. Therefore, it is of great clinical signi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-025-03821-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850243610802388992 |
|---|---|
| author | Xiaolu Xie Yaomin Wang Ziyi Wang Lei Zhang Jun Li Yaling Li |
| author_facet | Xiaolu Xie Yaomin Wang Ziyi Wang Lei Zhang Jun Li Yaling Li |
| author_sort | Xiaolu Xie |
| collection | DOAJ |
| description | Abstract Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. Although drug therapy has been well developed and applied, its clinical efficacy is limited due to primary or acquired drug resistance in most HCC patients. Therefore, it is of great clinical significance to elucidate the key molecular mechanisms of resistance and improve the sensitivity of HCC cells to drugs. At present, a variety of HCC drug resistance models have been developed to find out resistance mechanisms, screen biomarkers, and explore strategies to reverse drug resistance, including traditional HCC drug resistance models, HCC patient-derived drug resistance models, three-dimensional drug resistance models, transgenic drug resistance models, and multi-drug resistance models. Here, we searched PubMed, Embase and Web of science for studies related to HCC drug resistance models in recent years, systematically summarized the established methods and characteristics of these models, reviewed their applications and compared their advantages and disadvantages, aiming to provide reference for the selection of appropriate models for HCC drug resistance research. |
| format | Article |
| id | doaj-art-3db3136101df4dc99d93e16f3b101355 |
| institution | OA Journals |
| issn | 1475-2867 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj-art-3db3136101df4dc99d93e16f3b1013552025-08-20T01:59:57ZengBMCCancer Cell International1475-28672025-05-0125111210.1186/s12935-025-03821-yHepatocellular carcinoma drug resistance modelsXiaolu Xie0Yaomin Wang1Ziyi Wang2Lei Zhang3Jun Li4Yaling Li5Department of Pharmacy, Yibin Hospital Affiliated to Children’s Hospital of Chongqing Medical UniversityDepartment of Pharmacy, The Affiliated Hospital, Southwest Medical UniversityDepartment of Pharmacy, The Affiliated Hospital, Southwest Medical UniversityDepartment of Pharmacy, The Affiliated Hospital, Southwest Medical UniversityDepartment of Traditional Chinese Medicine, The Affiliated Hospital, Southwest Medical UniversityDepartment of Pharmacy, The Affiliated Hospital, Southwest Medical UniversityAbstract Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. Although drug therapy has been well developed and applied, its clinical efficacy is limited due to primary or acquired drug resistance in most HCC patients. Therefore, it is of great clinical significance to elucidate the key molecular mechanisms of resistance and improve the sensitivity of HCC cells to drugs. At present, a variety of HCC drug resistance models have been developed to find out resistance mechanisms, screen biomarkers, and explore strategies to reverse drug resistance, including traditional HCC drug resistance models, HCC patient-derived drug resistance models, three-dimensional drug resistance models, transgenic drug resistance models, and multi-drug resistance models. Here, we searched PubMed, Embase and Web of science for studies related to HCC drug resistance models in recent years, systematically summarized the established methods and characteristics of these models, reviewed their applications and compared their advantages and disadvantages, aiming to provide reference for the selection of appropriate models for HCC drug resistance research.https://doi.org/10.1186/s12935-025-03821-yHCCDrug resistanceCell linePatient-derived xenograftTransgenic model |
| spellingShingle | Xiaolu Xie Yaomin Wang Ziyi Wang Lei Zhang Jun Li Yaling Li Hepatocellular carcinoma drug resistance models Cancer Cell International HCC Drug resistance Cell line Patient-derived xenograft Transgenic model |
| title | Hepatocellular carcinoma drug resistance models |
| title_full | Hepatocellular carcinoma drug resistance models |
| title_fullStr | Hepatocellular carcinoma drug resistance models |
| title_full_unstemmed | Hepatocellular carcinoma drug resistance models |
| title_short | Hepatocellular carcinoma drug resistance models |
| title_sort | hepatocellular carcinoma drug resistance models |
| topic | HCC Drug resistance Cell line Patient-derived xenograft Transgenic model |
| url | https://doi.org/10.1186/s12935-025-03821-y |
| work_keys_str_mv | AT xiaoluxie hepatocellularcarcinomadrugresistancemodels AT yaominwang hepatocellularcarcinomadrugresistancemodels AT ziyiwang hepatocellularcarcinomadrugresistancemodels AT leizhang hepatocellularcarcinomadrugresistancemodels AT junli hepatocellularcarcinomadrugresistancemodels AT yalingli hepatocellularcarcinomadrugresistancemodels |